Firstkind Ltd will showcase its innovative wearable technology, the geko® device, at World Health Expo (WHX), highlighting its expanding role in wound care, vascular health and post-operative recovery.
The geko device uses a unique, non-invasive form of neuromuscular electrostimulation (NMES) to activate the calf and foot muscle pumps. By stimulating these muscles, the device increases venous, arterial and microcirculatory blood flow, helping to transport oxygenated blood to the wound bed. This mechanism has been shown to accelerate healing in patients with chronic venous insufficiency and intermittent claudication, while also reducing pain and oedema.
“Chronic wounds and post-operative oedema place a significant burden on patients and healthcare systems alike,” said Fiona Young, Business Director, Wound Therapy for Firstkind Ltd
“The evidence behind the geko device shows that by addressing the underlying circulatory challenges, we can significantly improve healing outcomes, reduce pain and support earlier, more effective intervention. WHX 2026 provides an important opportunity to share this data directly with clinicians who are facing these challenges every day.”
Clinical evidence shows that the geko device can double the rate of healing in venous leg ulcers (VLUs) when used alongside standard multi-layer compression therapy, compared with compression alone. For patients with VLUs, use of the device has been associated with rapid pain reduction, faster healing and improved concordance with treatment.
Beyond wound care, the geko device has demonstrated benefits across multiple clinical settings. It has been shown to reduce the risk of venous thromboembolism (VTE) in acute stroke patients and to prevent the build-up of post-operative oedema following orthopaedic procedures, including knee and foot and ankle surgery. These benefits support enhanced recovery after surgery (ERAS) pathways, helping patients mobilise sooner and potentially reducing overall clinical burden.
At WHE 2026, Firstkind Medical aims to share the latest clinical data supporting the geko device, including results from its published multi-centre randomised self-controlled trial demonstrating significantly improved healing outcomes in venous leg ulcer patients.
The team will also highlight the orthopaedic applications of the technology, particularly its role in managing post-operative oedema and supporting recovery following lower limb surgery. Live product demonstrations will take place throughout the event, featuring both the geko T3 device for orthopaedic use and the geko W3 device for wound healing, alongside opportunities for in-depth Q&A with clinical experts.
Firstkind Ltd presence at WHX 2026 will be focused on engaging with clinical decision makers, including vascular surgeons, wound care specialists, general surgeons and orthopaedic surgeons. The company is committed to working in partnership with healthcare professionals to address complex clinical challenges, support earlier intervention and contribute to more sustainable and effective care pathways.
For more information visit www.gekodevices.com
